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Abstract
The clinical manifestations of cerebral malaria (CM) are well correlated with underlying major pathophysiological
events occurring during an acute malaria infection, the most important of which, is the adherence of parasitized
erythrocytes to endothelial cells ultimately leading to sequestration and obstruction of brain capillaries. The
consequent reduction in blood flow, leads to cerebral hypoxia, localized inflammation and release of neurotoxic
molecules and inflammatory cytokines by the endothelium. The pharmacological regulation of these
immunopathological processes by immunomodulatory molecules may potentially benefit the management of this
severe complication. Adjunctive therapy of CM patients with an appropriate immunomodulatory compound
possessing even moderate anti-malarial activity with the capacity to down regulate excess production of
proinflammatory cytokines and expression of adhesion molecules, could potentially reverse cytoadherence, improve
survival and prevent neurological sequelae. Current major drug discovery programmes are mainly focused on novel
parasite targets and mechanisms of action. However, the discovery of compounds targeting the host remains a
largely unexplored but attractive area of drug discovery research for the treatment of CM. This review discusses the
properties of the plant immune-modifier curcumin and its potential as an adjunctive therapy for the management
of this complication.
Background
Malaria, a disease caused by the Apicomplexan parasite of
the genus Plasmodium, remains a serious public health
threat in tropical and sub-tropical countries. It is the most
important parasitic disease in humans with 300 to 500 mil-
lion infected individuals every year. A proportion of
these patients, mostly children under five, is at risk of
developing severe anaemia or cerebral malaria (CM),
which claims at least 1 million lives annually [1]. CM is a
life-threatening complication of this infection which often
occurs in non-immune individuals and those in which
standard anti-malarial treatment has failed [2]. The effec-
tiveness of anti-malarial treatment has been hampered by
the emergence over the years of parasites resistant to
almost all available anti-malarial drugs, including more
lately the artemisinin class of drugs [3]. The reduced
susceptibility to artemisinin derivatives recently identified
in parasite isolates from SE Asia may compromise their
efficacy for the treatment of CM, which currently relies on
artesunate or quinine [4], and is a worrying sign, as resis-
tance may spread quickly to other parts of the world.
Treatment failure of uncomplicated cases will inevitably
increase the number of patients susceptible to develop
severe complications. Therefore, there is an urgent need to
develop new anti-malarial drugs and drug combinations or
alternative strategies that circumvent the development of
parasite drug resistance with the final aim of reducing
the burden of this disease. These approaches may involve
the identification of immune-modifying compounds with
the capacity of enhancing macrophage’sp h a g o c y t i ca c t i v i t y ,
resulting in a reduction of the parasite biomass [5], down-
regulating excessive pro-inflammatory type 1 response, and
reducing the expression of adhesion molecules and subse-
quent sequestration of parasitized erythrocytes (PE) (a
hallmark of human CM) in the cerebral microvasculature,
thus improving survival of CM patients. Targeting the
host, using immunomodulatory compounds, might be a
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activity of standard anti-malarial drugs and, as such, pre-
sent a valuable tool in the management of CM and limit
the emergence of resistant parasites. This review highlights
the potential benefits that the plant-based natural product
c u r c u m i nm a yh a v ea sa ni m m u n o m o d u l a t o ra n da sa n
adjunctive therapy for CM.
Rationale for the use of immunomodulators for the
treatment of cerebral malaria
Cerebral malaria, one of the most severe complications
of Plasmodium falciparum infections, is associated with
various pathophysiological processes [6]. CM is mostly
characterized by hyper-parasitaemia and by an excessive
production of type 1 pro-inflammatory cytokines fol-
lowed by up-regulation of endothelial cell adhesion
molecule expression which contributes to the sequestra-
tion of PE in the brain microvasculature [7]. Under-
standing the molecular events implicated in the onset of
CM would pave the way for the development of adjunc-
tive therapies that may reduce cerebral damage by mod-
ulation of the pathological processes involved in its
development, and thus prevent subsequent mortality
and neurological sequalae. The association of immuno-
modulators with anti-malarial drugs could prove to be
beneficial for the management of this condition [8].
This approach has already been tested using a variety of
compounds in animal models of experimental cerebral
malaria (ECM) [9-13] as well as in humans [14,15]. One
of the strategies currently being investigated is to target
the peroxisome proliferator activated receptor gamma
(PPARg), a nuclear receptor involved in the regulation
of the scavenger receptor CD36, which mediates non-
opsonic phagocytosis of PE [16]. Pharmacological upre-
gulation of CD36 in monocytes/macrophages by PPARg
agonists increases CD36 dependant phagocytosis of PE
in vitro [17]. In a murine model of malaria, administra-
tion of the PPARg agonist rosiglitazone, to Plasmodium
chabaudi-infected mice, significantly decreased parasi-
taemia levels in wild type compared to CD36 knock-out
mice and improved survival in Plasmodium berghei-
ANKA infected groups [12]. These findings warranted a
randomized, double-blind, placebo-controlled trial to
assess the efficacy of rosiglitazone, as an adjunctive ther-
apy for the treatment of P. falciparum malaria. That
trial showed a reduction in parasite clearance time and
inflammatory markers in patients with uncomplicated
malaria under a treatment regimen consisting of atova-
quone + rosiglitazone compared to patients treated with
atovaquone + placebo [18]. This evidence, together
with a recent genome-wide association study linking a
locus containing PPARg with improved survival in a
rodent malaria model [19], led us to speculate that
pharmacologically targeting the signalling pathways
involved in PPARg/CD36 expression during a malarial
infection might improve CM treatment outcome.
Erythropoietin (Epo), a hormone produced by the kid-
neys which modulates the survival of developing ery-
throid precursors and production of new erythrocytes in
the bone marrow, has been explored for the manage-
ment of CM in animals and humans [9]. In the P. ber-
ghei-ANKA murine model of ECM, injection of high
doses of Epo at the beginning of symptoms, significantly
reduced the expression of pro-inflammatory cytokines
(TNF and Interferon-g)a n di m p r o v e dt h es u r v i v a lo f
mice with ECM compared to untreated mice [20].
Furthermore, in the same murine model of ECM, the
doses of Epo were decreased six fold and its administra-
tion combined with artesunate was delayed to the sixth
day post-infection. The results indicated that the survi-
val rate was higher in mice receiving the combination
Epo-artesunate than in mice treated with artesunate
alone [21]. Clinical evidence for a neuroprotective role
of Epo in humans emerged from a study of African
children with CM in which high plasma levels of Epo
were associated with a 70% reduction of the risk of
being discharged with neurological sequelae [22]. These
findings provided preliminary evidence for a clinical
trial assessing the safety of Epo as an adjunctive therapy
for children with CM in Mali. In this trial, the adminis-
tration of high doses of Epo in CM children did not
result in any side effects when evaluated on a short-
term basis, and no significant increase in the case fatal-
ity rate of the combined Epo-quinine administration
was observed [15].
Activated charcoal is also being explored as a potential
adjunctive therapy for the treatment of CM. Oral acti-
vated charcoal (oAC) is highly effective at adsorbing a
range of endotoxin-induced cytokines from the blood-
stream including TNF, IL-1 and IL6 [23,24]. It was
recently found that oAC protected mice against ECM
and more importantly did not interfere with the phar-
macokinetics of parenteral artesunate in humans [10].
The fact that oAC is a safe and well-tolerated com-
pound already used in the clinic may accelerate its
development as an adjunctive therapy for CM. Alterna-
tively, the Rho-Kinase inhibitor, Fasudil, a drug
approved for human use for cardio- and neuro-vascular
diseases, is being proposed as an adjunctive therapy for
severe malaria. Fasudil, which has anti-apoptogenic
properties, protects and restores in vitro, the damage to
the endothelial barrier resulting from PE adhesion
[25,26]. It is worth mentioning that the adhesion of PE
to human endothelial cells activates Rho Kinases and
caspases leading to apoptosis [27]. Furthermore, Fasudil
also modulates CM in P. berghei-ANKA infected mice
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also involved in the pathology of CM and supplementa-
tion with anti-oxidant compounds protected endothelial
cells in vitro[28]. In addition, treatment of P. berghei-
infected mice with the antioxidant N-acetylcysteine
(NAC) or the iron chelator, deferoxamine, in combina-
tion with chloroquine at the first signs of CM,
prevented the development of persistent cognitive dys-
function in infected mice [11]. However, a clinical trial
of NAC in combination with artesunate as adjunct ther-
a p yf a i l e dt od e t e c ta n yb e n e f i to no u t c o m ei np a t i e n t s
with severe P. falciparum malaria [14]. Although all
these treatment options for adjunctive therapies in CM
seem promising (for a detailed review of adjunctive
therapies for malaria see [8, 29-30]), none of these com-
pounds possess specific anti-malarial activity on their
own. Therefore, plant-based immunomodulators display-
ing dual anti-malarial and immunodulatory mechanisms
of action could become ideal candidates for anti-malarial
drug development. This strategy has been explored with
the natural product curcumin which shows immunomo-
dulatory properties and has been found to prevent death
from CM in P. berghei infected mice [13].
Curcumin, a plant-based immunomodulator
For thousands of years, some of the most effective anti-
malarial drugs have been derived from plants. Quinine
and artemisinin, the only two molecules of choice for
the treatment of severe malaria were isolated from the
bark of the cinchona tree and the Chinese plant Artemi-
sia annua, respectively. Although artemisinin and its
derivatives have had a major impact on treatment when
given in combination with other anti-malarials, they are
limited by their short half-life, cost and safety concerns
in pregnant women [31]. Poor distribution and access to
these drugs among the population living in malaria
endemic areas, means that many still rely on numerous
herbal preparations or diets from traditional healers for
the management of fever and malaria [32].
The natural product curcumin (1,7-bis(4-hydroxy
3-methoxy phenyl)-1,6-heptadiene-3,5-dione) is a
polyphenolic compound extracted from the rhizome of
Curcuma longa L. (family Zingiberaceae) (Figure 1)
commonly used in the Asian sub-continent, especially in
India, as a dietary spice to provide colour and flavour
[33]. In traditional Indian medicine (Ayurveda), curcu-
min has been considered an effective drug for the
Curcuma longa Curcumin-based products
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Figure 1 Chemical structure of curcumin. Curcumin (diferuloylmethane) is the active principle of the perennial herb Curcuma longa also
known as turmeric (A) and is extracted from its roots (B). Molecular structure of curcumin (C). Curcumin-based products are available as dietary
supplements (D). Curcuma longa photos © Merlin Willcox.
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substantiated and provided scientific evidence regarding
its prophylactic and therapeutic potential, unravelling
the anti-inflammatory, anti-carcinogenic, and anti-infec-
tious activities of this natural product (Reviewed in
[33-35]).
Curcumin for malaria therapy?
Studies carried out both in vitro and in vivo indicated
that curcumin possesses a moderate anti-malarial activ-
ity with an IC50 ranging from 5-10µM in vitro[36,37],
[38]. In order to expand its potential as anti-malarial,
curcumin derivatives have been synthesized and some
of them demonstrated an increased anti-malarial activity
in vitro with an IC50 of ~400nM [39]. It was then
demonstrated that this compound inhibits histone acet-
yltransferase (HAT) and increases the production of
reactive oxygen species (ROS) in the malaria parasite
[36]. Despite its moderate anti-malarial activity, other
investigators suggested that the mechanism of action of
curcumin might mirror that of artemisinin. In fact, arte-
misinin derivatives seem to target the parasite mito-
chondria and the flavin co-factors thus increasing the
production of ROS. This reactivity is dependent on the
endoperoxide bridge, which is essential for the anti-
malarial activity of artemisinins [40,41]. Curcumin
s e e m st ob em o r ee f f e c t i v ei nk i l l i n gt h em a l a r i ap a r a -
site at the trophozoite stage while artemisinins display
broad activity against all stages of the intraerythrocytic
development of the malaria parasite [38]. Molecular
docking experiments showed that curcumin can effi-
ciently bind the malaria sarco-endoplasmic reticulum
calcium ATPase (SERCA-PfATPase6) [42,43] an ATP
coupled Ca
2+ ion pump involved in metabolic arrest
which was first thought to be the biological target of
artemisinin [44-46]. Interestingly, oral administration of
curcumin followed by a single injection of the artemisi-
nin derivative a-b-arteether to P. berghei-infected mice,
prevented recrudescence usually associated with a-b-
arteether monotherapy and ensured almost 100% survi-
val of animals [47]. By contrast, a subsequent study
showed that although curcumin had modest anti-malar-
ial efficacy (delay in the peak parasitaemia) in mice, it
was not able to modify the course of infection, when
administered with artemisinin nor to reverse a P. cha-
baudi artemisinin-resistant phenotype [48]. The modest
anti-malarial activity of curcumin in this model system
was attributed to its immunomodulatory activities,
which could be beneficial in delaying parasite growth.
However, inherent differences between the two experi-
mental murine models may help explain these contra-
dicting results, since in contrast to P berghei -ANKA,
Pc h a b a u d icauses a non lethal infection and does not
lead to CM in CD1 mice [48].
Curcumin as an adjunctive therapy for severe/cerebral
malaria infection
Curcumin as a modulator of the innate immune response
to malaria infection
The severity of malaria infections is often associated
with a large parasite biomass which triggers defence
mechanisms that hinder parasite multiplication and
are, therefore, important contributing factors in host
survival [49]. A key feature of curcumin is that it pos-
sesses both anti-oxidant and pro-oxidant activities
[50,51]. Available evidence supporting a protective role
of ROS in malaria has emerged from animal and
human studies. In humans, the elevated production of
oxygen radicals was associated with faster parasite
clearance in children with uncomplicated P. falciparum
malaria [52]. Furthermore, in the athymic or scid/bg
mouse model of malaria, a pro-oxidant vitamin E-defi-
cient diet enriched with fish oil suppressed a lethal
P. yoelii infection [53]. Although the actual molecular
events leading to protection from malaria in mice fed
this pro-oxidant diet were not elucidated, an enhanced
pro-oxidant activity in these animals could have either
directly killed the parasites or activated signalling path-
ways that could have contributed to the killing of PE
via non-opsonic phagocytosis. In fact, ROS increase
the expression of the scavenger receptor CD36 in
monocytes/macrophages [54] and CD36 mediates non-
opsonic phagocytosis of PE by macrophages [16,55].
In addition to its specific anti-malarial activity, the
immunomodulatory properties of curcumin affect var-
ious cell types of the immune system [Reviewed in [56]).
When administered in vivo to mice, a significant
increase in macrophage phagocytic activity was observed
[57]. Furthermore, curcumin increased non-inflamma-
tory phagocytosis of latex beads in murine macrophages
in vitro[58]. From the same perspective, it was demon-
strated that curcumin increased the surface expression
of CD36 on human monocytes/macrophages and CD36-
dependent phagocytosis through a transient production
of ROS which was downregulated by the anti-oxidant
NAC [38]. Thus, these findings partly support the view
that CD36 can be seen as a marker of the enhanced
macrophage phagocytic activity observed in curcumin-
treated animals [57]. CD36 expression is regulated either
by activation of the nuclear receptor PPARg or by the
redox-sensitive transcription factor nuclear related {ery-
throid-derived 2} factor (Nrf2) [17,59]. Interestingly,
these two transcription factors have been found to be
activated in curcumin-treated monocytes/macrophages
[60,61], though experimental evidence suggested that
curcumin is not a genuine PPARg agonist [62]. To sum-
marize, it is likely that curcumin enhances discrete fac-
tors implicated in the innate immune response to
malaria infection (e.g CD36) via a cascade of events
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PPARg/Nrf2 activation and upregulation of monocytes/
macrophages CD36 surface expression and enhanced
phagocytosis of PE (Figure 2).
Curcumin downregulates proinflammatory cytokine
responses and expression of adhesion molecules on human
endothelial cells in vitro
Cerebral malaria is the result of deleterious patholo-
physiological processes that take place in a Plasmo-
dium-infected host [6]. In human malaria, a consistent
histological finding in CM in both children and adults
is the presence of infected and non-infected erythro-
cytes packed within cerebral microvessels [63]. This
sequestration of PE and non-infected erythrocytes
reduces the microvascular flow thereby causing disrup-
tion of blood brain barrier, cerebral oedema and tissue
hypoxia [30, 63-64]. In addition, the release of neuro-
toxic and inflammatory mediators that may leak across
the blood-brain barrier and cause more damage to the
microvascular endothelium also contribute to this
pathology (reviewed in [6]). The sequestration process
is the result of increased expression of cytoadhesion
molecules mainly ICAM1, VCAM1 and E-selectin on
brain endothelial cells stimulated by the overproduc-
tion of inflammatory cytokines [65] or by the direct
adhesion of P. falciparum to endothelial cells [66]. In
fact, adhesion of P. falciparum to human brain
endothelial cells in vitro creates an inflammatory envir-
onment via stimulation of NF-Bw h i c hi nt u r nu p r e -
gulates expression of ICAM1 [66,67]. Most of the
adjunctive therapies for the management of CM have
been tested in mice and careful precautions should be
taken when extrapolating findings from animal models
to human CM [68]. However, some of the key features
of human CM can also be replicated in the P. berghei
model as discussed by Riley at al [69], making it rea-
sonably suitable for preliminary evaluation of potential
CM adjunctive therapies.
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Figure 2 Schematic diagram illustrating the main biological targets of curcumin that can be exploited in suppressing
immunopathological events associated with cerebral malaria. Upon exposure of cells to curcumin, a transient induction of reactive oxygen
species (ROS) may occur. This potentially leads to activation of a signalling cascade involving the peroxisome proliferator activated receptor
gamma (PPARg) and induction of the redox-sensitive factor Nrf2. Activated-Nrf2 and PPARg translocate in the nucleus, where they bind to their
target genes via their respective binding sites,the anti-oxidant response element (ARE) for Nrf2 and the peroxisome proliferator response element
(PPRE) for PPARg. In monocytes/macrophages activation of Nrf2 or PPARg will lead to upregulation of the surface expression of CD36, increasing
their phagocytic activity [55]. In other cell types such as endothelial cells, activation of Nrf2 and PPARg may lead to upregulation of
cytoprotective enzymes [haem oxygenase 1 (HO-1), NADPH quinine oxidoreductase-1 (NQ-1), gamma-glutamate cysteine ligase (g-GCL)],
counteracting free radical-induced damage and exerting a neuroprotective effect [87]. On the other hand, PPARg (solid arrows) and perhaps Nrf2
(dashed arrows) could exert their anti-inflammatory activities by inhibiting NF-B activation, thereby downregulating proinflammatory cytokine
responses and adhesion molecule expression which are all implicated in the pathology of CM.
Mimche et al. Malaria Journal 2011, 10(Suppl 1):S10
http://www.malariajournal.com/content/10/S1/S10
Page 5 of 9Curcumin exhibits profound anti-inflammatory activ-
ities due to inhibition of NF-B activation [70]. This can
explain the rationale for the use of curcumin in Ayur-
veda as a treatment for chronic inflammatory diseases
[71]. This immunomodulatory property of curcumin
may be useful in protecting the brain endothelium from
the damages caused by the sequestration of PE. Curcu-
min administered in conjunction with the standard
treatment for CM, artesunate or quinine, might contri-
bute to the reversal of parasite sequestration and infla-
mamtion, reducing the risk of neurological sequaelae.
Interestingly, administration of curcumin (50mg/kg,
twice a day for 6 days post infection) to C57Bl/6 mice
infected with P. berghei-ANKA prevented CM and
delayed death by 10 days [13]. In addition, it has been
shown in vitro that curcumin reduces the production of
proinflammatory cytokines TNF, IL12p40 and IL6 in
PBMC primed with trophozoites/schizonts stages of
P. falciparum and downregulated the expression of
ICAM1, VCAM1 and E-selectin in TNF-activated
human endothelial cells [38]. The down regulation of
proinflammatory cytokines and adhesion molecules
observed following PBMC exposure to curcumin
in vitro, is perhaps the result of Nrf2 or PPARg activa-
tion which exert anti-inflammatory actions by blocking
NF-B activation (Figure 2) [72]. In fact, in an animal
model of traumatic brain injury it was observed that
Nrf2 deficient mice have enhanced NF-B activation,
inflammatory cytokine production and increased ICAM-
1 expression in the brain compared to their wild type
counterparts [73]. Furthermore, induction of haem oxy-
g e n a s e1( H O - 1 )w h i c hi sad o w n s t r e a mt a r g e to ft h e
Nrf2 activation cascade (Figure 2) suppressed the
pathology of ECM in mice [74] while activating Nrf2
pathway was demonstrated to be a potential therapeutic
target in brain inflammation [75]. Curcumin inhibits the
adhesion of thrombin-activated platelets to brain micro-
vascular endothelial cells in vitro[76] which are thought
to accumulate in the brain microvasculature in murine
and paediatric CM patients [77]. Recent genome wide
analysis studies of inbred mouse lines confirming the
important role that PPARg might have in malarial survi-
val [19], support a therapeutic approach in which the
targeting of this transcription factor (using curcumin for
example) could be useful in the management of CM. In
addition to PPARg, it might be worth investigating the
effect of targeted deletion of Nrf2 in brain microvascular
endothelial cells in vitro as well as in vivo in order to
validate the Nrf2 activation pathway as an additional
therapeutic target for CM.
In malaria endemic areas, both severe malaria and
sepsis may often occur together [78]. In an animal
model of sepsis, disruption of Nrf2 was associated with
a significant increase in proinflammatory cytokines and
mortality in response to endotoxin-induced septic shock
[79]. Management of severe malaria and sepsis could be
supported with anti-inflammatory agents that may target
Nrf2, such as curcumin, in combination with potent
artemisinin derivatives. In fact, artemisinins also possess
significant anti-inflammatory activity suppressing TNFa
and IL-6 in a murine model of sepsis [80]. Moreover,
the artemether-lumefantrine combination has been
found to decrease mortality from sepsis in Ugandan
children without malaria [81]. In a recent multicentre,
open label, randomised trial comparing artesunate ver-
sus quinine (Aquamat Study) for the treatment of severe
P. falciparum malaria in African children, intravenous
artesunate has now been declared to be the most effec-
tive treatment for severe malaria [4]. This gives support
to our view that if appropriately developed and
approved for human use, curcumin or more potent deri-
vatives could potentially be used with artesunate in the
future. An open-labelled study to evaluate the safety of
future curcumin formulations, combined with intrave-
nous artesunate, examining as endpoints neurological
sequelae or survival rate, should be carried out in future.
Since treatment for CM is initiated after the onset of
coma in most cases, it will be important to evaluate
whether curcumin can reverse or shorten the comatose
period and/or reduce the risk of neurological sequelae.
We anticipate that due to its specific anti-malarial activ-
ity, it is unlikely that curcumin will exacerbate the evo-
lution of CM.
Limitations for the use of curcumin in the clinic
Although the information discussed above suggests a
plausible and beneficial use of curcumin in the manage-
ment of CM, an important limitation hindering the clin-
ical advancement of this promising molecule is its poor
ADME properties. Curcumin shows low oral bioavail-
ability, high tissue distribution, rapid metabolism and
elimination [57,82]. The low bioavailability of curcumin
is in part due to its hydrophobic nature and when admi-
nistered orally, curcumin undergoes conjugation leading
to the formation of curcumin glucuronide and sulfates
in the intestinal wall and the liver [35]. Numerous stra-
tegies are currently being investigated to enhance curcu-
min’s bioavailability. One of these approaches involved
the use of a bioavailability enhancer such as piperine
from black pepper. Piperine is an inhibitor of hepatic
and intestinal glucuronidation which has enhanced the
bioavailability of curcumin when administered in animal
and human volunteers [83]. Other attempts to increase
curcumin’s bioavailability include liposomal curcumin
[84], curcumin nanoparticles and curcumin-phospholi-
pid complexes [85]. Thus, a successful enhancement of
curcumin bioavailability that preserves its safety in
humans is likely to bring this promising natural product
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of various conditions including malaria.
Concluding remarks
Curcumin has a long history of therapeutic use in the
Ayurvedic and Chinese traditional medicine and multi-
ple clinical trials are ongoing to evaluate its efficacy in
the management of various human disorders including
cancer, neurodegenerative diseases and diabetes [56] .
Curcumin is considered a safe compound by the United
States Food and Drug Administration and is commer-
cially available as a dietary supplement (Figure 1).
Curcumin is well-tolerated in humans and with respect
to the management of CM might exert its therapeutic
effects by inhibiting NF-B activation, followed by
downregulation of proinflammatory cytokine production
and expression of cytoadhesion molecules on endothelial
cells. The fact that cytoadherence of the malaria parasite
continues long after parasites have been killed by anti-
malarial drugs, supports the development of adjunctive
therapies to reverse the pathophysiological consequences
of cytoadherence [86]. With extensive research efforts
ongoing to explore the clinical applications of curcumin
in chronic inflammatory disorders, diabetes and cancer,
the development of oral and parenteral curcumin
formulations or curcumin analogues with improved
bioavailability while retaining their immunomodulatory
properties and possibly more potent anti-malarial activ-
ity deserves investigation. Drug discovery efforts focused
on molecules with dual, immunomodulatory and anti-
parasitic action, may pave the way for their use as an
adjunctive therapy for the management of uncompli-
cated and severe malaria.
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